PAF-acether specific binding sites: 2. Design of specific antagonists
- 31 December 1986
- journal article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 7, 397-403
- https://doi.org/10.1016/0165-6147(86)90401-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988European Journal of Pharmacology, 1986
- Inhibition of the vascular actions of IgG aggregates by BN 52021, a highly specific antagonist of paf-acetherImmunopharmacology, 1985
- Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021Biochemical and Biophysical Research Communications, 1985
- Association of Platelet-Activating Factor with Primary Acquired Cold UrticariaNew England Journal of Medicine, 1985
- Specific binding sites for platelet activating factor in human lung tissuesBiochemical and Biophysical Research Communications, 1985
- Is platelet activating factor (PAF) a mediator of endotoxin shock?European Journal of Pharmacology, 1985
- Effect of 1-alkyl-2-acetyl--glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the ratLife Sciences, 1984
- Inhibition by sulphinpyrazone of the platelet-dependent bronchoconstriction due to platelet-activating factor (PAF-acether) in the guinea-pigEuropean Journal of Pharmacology, 1982
- BACKGROUND AND PRESENT STATUS OF RESEARCH ON PLATELET‐ACTIVATING FACTOR (PAF‐ACETHER)Annals of the New York Academy of Sciences, 1981
- The ginkgolides. III. The structure of the ginkgolidesTetrahedron Letters, 1967